Correlated suppression by 5-bromodeoxyuridine of tumorigenicity and plasminogen activator in mouse melanoma cells
- PMID: 123336
- PMCID: PMC432237
- DOI: 10.1073/pnas.72.1.47
Correlated suppression by 5-bromodeoxyuridine of tumorigenicity and plasminogen activator in mouse melanoma cells
Abstract
The decrease of tumorigenicity by mouse melanoma clone B559 after growth in the presence of 5-bromodeoxyuridine (BrdU) has been correlated with a decrease in detectable cellular plasminogen activator. Reduction of both activities occurs after one to two cell divisions in the presence of this thymidine analog and is virtually complete within three to four cell cycles. These changes are fully reversible; four to five cell divisions in the absence of BrdU are sufficient to allow both tumorigenicity and plasminogen activator levels to return to normal. These results support the hypotheses that (a) the expression of a cellular plasminogen activator is closely associated with the transformation of normal to malignant cells and that (b) the suppression of tumorigenicity by BrdU reflects the capacity of this base analog to inhibit the expression of specialized functions which accompany the malignant state.
Similar articles
-
Co-cultivation of tumorigenic mouse melanoma cells with cells of a non-tumorigenic subclone inhibits plasminogen activator expression by the melanoma cells.J Cell Physiol. 1978 May;95(2):159-67. doi: 10.1002/jcp.1040950205. J Cell Physiol. 1978. PMID: 206566
-
Suppression of melanoma cell tyrosinase activity and tumorigenicity after incorporation of bromouracil for one or two cell divisions.J Cell Physiol. 1975 Dec;86 Suppl 2(3 Pt 2):581-92. doi: 10.1002/jcp.1040860503. J Cell Physiol. 1975. PMID: 811676
-
Malignant mouse melanoma cells do not form tumors when mixed with cells of a non-malignant subclone: relationships between plasminogen activator expression by the tumor cells and the host's immune response.J Cell Physiol. 1978 May;95(2):169-77. doi: 10.1002/jcp.1040950206. J Cell Physiol. 1978. PMID: 306389
-
Effects of 5-bromodeoxyuridine on tumorigenicity, immunogenicity, virus production, plasminogen activator, and melanogenesis of mouse melanoma cells.Int Rev Cytol. 1976;45:65-111. doi: 10.1016/s0074-7696(08)60078-9. Int Rev Cytol. 1976. PMID: 821894 Review. No abstract available.
-
Tumor growth and metastases in malignant disease. A review.J Med. 1988;19(3-4):179-91. J Med. 1988. PMID: 3141546 Review.
Cited by
-
Tumorigenicity of herpesvirus-transformed cells correlates with production of plasminogen activator.Mol Cell Biol. 1981 May;1(5):408-17. doi: 10.1128/mcb.1.5.408-417.1981. Mol Cell Biol. 1981. PMID: 6100964 Free PMC article.
-
Direct fluorescent assay of urokinase and plasminogen activators of normal and malignant cells: kinetics and inhibitor profiles.Proc Natl Acad Sci U S A. 1978 Feb;75(2):750-3. doi: 10.1073/pnas.75.2.750. Proc Natl Acad Sci U S A. 1978. PMID: 204931 Free PMC article.
-
Modulation of cell-associated plasminogen activator activity by cocultivation of a stem cell and its tumorigenic descendant.Mol Cell Biol. 1984 Jan;4(1):160-5. doi: 10.1128/mcb.4.1.160-165.1984. Mol Cell Biol. 1984. PMID: 6538259 Free PMC article.
-
Tumor regression at an untreated site during immunotherapy of an identical distant tumor.Proc Natl Acad Sci U S A. 1975 Sep;72(9):3680-2. doi: 10.1073/pnas.72.9.3680. Proc Natl Acad Sci U S A. 1975. PMID: 171671 Free PMC article.
-
Immunological analysis of plasminogen activators from normal and transformed hamster cells. Evidence that the plasminogen activators produced by SV40 virus-transformed hamster embryo cells and normal hamster lung cells are antigenically identical.J Exp Med. 1975 Aug 1;142(2):419-34. doi: 10.1084/jem.142.2.419. J Exp Med. 1975. PMID: 49388 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
